This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lacy, M. K.
Right arrow Articles by Quintiliani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacy, M. K.
Right arrow Articles by Quintiliani, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1999, p. 3005-3007, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Oral Bioavailability and Pharmacokinetics of Trovafloxacin in Patients with AIDS

Melinda K. Lacy,1 David P. Nicolau,2,3,* Charles H. Nightingale,2,4 Amy Geffken,5 Renli Teng,5 John Vincent,5 and Richard Quintiliani4

Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, Kansas 661601; Department of Pharmacy Research,2 Office for Research Administration,4 and Division of Infectious Diseases,3 Hartford Hospital, Hartford, Connecticut 06102; and Pfizer Central Research, Groton, Connecticut 063405

Received 22 March 1999/Returned for modification 24 July 1999/Accepted 8 September 1999

Trovafloxacin pharmacokinetics were evaluated in 12 subjects with AIDS. By using a randomized design, single 200-mg doses of oral trovafloxacin and intravenous alatrofloxacin were administered. The mean absolute bioavailability was 91%. The pharmacokinetics of trovafloxacin when administered orally as the active form or intravenously as the prodrug (alatrofloxacin) are not altered in subjects with AIDS compared to those in healthy adults.


* Corresponding author. Mailing address: Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102. Phone: (860) 545-3941. Fax: (860) 545-5112. E-mail: dnicola{at}harthosp.org.


Antimicrobial Agents and Chemotherapy, December 1999, p. 3005-3007, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]